Non-arteritic posterior ischemic optic neuropathy (NA-PION) is a disorder of reduced blood flow to the retrobulbar optic nerve. There is usually an acute loss of visual acuity and field. Previous studies have noted an improvement in visual acuity and in ocular and retrobulbar blood flow with the use of a potent vasodilator of the microcirculation, prostaglandin E1 (PGE1), and steroids. The current report describes immediate improvement in the visual fields and visual acuity in a patient with NA-PION treated with intravenous PGE1 and steroids 66 hours after onset. An 89-year-old white female was first seen in December 2016 with a sudden loss of vision in the right eye. After a complete eye exam and visual fields, the patient was diagnosed with NA-PION. Treatment was immediately started with steroids and intravenous PGE1. This was repeated once again the next morning. Visual acuity in the right eye improved from 1/10 + 1 to 7/10 + 3 at 5 days. The mean deviation of the visual field improved from – 7.10 decibels (dB) with a central scotoma of – 22 dB to – 2.97 dB with a central scotoma of – 19 dB. After 2 weeks, her visual acuity was 7/10 + 1 and visual field testing of the right eye revealed a mean deviation of – 2.54 dB with a central scotoma of – 9 dB. The left eye was unchanged. In cases of NA-PION, PGE1 and steroids should be considered to immediately restore blood flow to help improve visual acuity and visual fields.

Visual field improvement in non-arteritic posterior ischemic optic neuropathy in a patient treated with intravenous prostaglandin E1 and steroids / Steigerwalt Robert Davis, J; Limoli Paolo, Giuseppe; Nebbioso, Marcella. - In: DRUG DISCOVERIES & THERAPEUTICS. - ISSN 1881-7831. - STAMPA. - 11:4(2017), pp. 226-229. [10.5582/ddt.2017.01034]

Visual field improvement in non-arteritic posterior ischemic optic neuropathy in a patient treated with intravenous prostaglandin E1 and steroids

Nebbioso Marcella
Ultimo
Supervision
2017

Abstract

Non-arteritic posterior ischemic optic neuropathy (NA-PION) is a disorder of reduced blood flow to the retrobulbar optic nerve. There is usually an acute loss of visual acuity and field. Previous studies have noted an improvement in visual acuity and in ocular and retrobulbar blood flow with the use of a potent vasodilator of the microcirculation, prostaglandin E1 (PGE1), and steroids. The current report describes immediate improvement in the visual fields and visual acuity in a patient with NA-PION treated with intravenous PGE1 and steroids 66 hours after onset. An 89-year-old white female was first seen in December 2016 with a sudden loss of vision in the right eye. After a complete eye exam and visual fields, the patient was diagnosed with NA-PION. Treatment was immediately started with steroids and intravenous PGE1. This was repeated once again the next morning. Visual acuity in the right eye improved from 1/10 + 1 to 7/10 + 3 at 5 days. The mean deviation of the visual field improved from – 7.10 decibels (dB) with a central scotoma of – 22 dB to – 2.97 dB with a central scotoma of – 19 dB. After 2 weeks, her visual acuity was 7/10 + 1 and visual field testing of the right eye revealed a mean deviation of – 2.54 dB with a central scotoma of – 9 dB. The left eye was unchanged. In cases of NA-PION, PGE1 and steroids should be considered to immediately restore blood flow to help improve visual acuity and visual fields.
2017
non-arteritic posterior ischemic optic neuropathy; prostaglandin E1; visual field; central scotoma
01 Pubblicazione su rivista::01i Case report
Visual field improvement in non-arteritic posterior ischemic optic neuropathy in a patient treated with intravenous prostaglandin E1 and steroids / Steigerwalt Robert Davis, J; Limoli Paolo, Giuseppe; Nebbioso, Marcella. - In: DRUG DISCOVERIES & THERAPEUTICS. - ISSN 1881-7831. - STAMPA. - 11:4(2017), pp. 226-229. [10.5582/ddt.2017.01034]
File allegati a questo prodotto
File Dimensione Formato  
Steigerwalt_Visual field improvement_2017.pdf

accesso aperto

Note: https://www.jstage.jst.go.jp/article/ddt/11/4/11_2017.01034/_pdf/-char/en
Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 628.31 kB
Formato Adobe PDF
628.31 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1044456
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 2
social impact